| AEs | adverse events |
| ALK | anaplastic lymphoma kinase |
| AST | aspartate aminotransferase |
| ATA | American Thyroid Association |
| ATC | anaplastic thyroid cancer |
| BMI | body mass index |
| BRAF | B-Raf proto-oncogene |
| CT | computer tomography |
| CTLA-4 | cytotoxic T-lymphocyte antigen-4 |
| DeTC | dedifferentiated thyroid cancer |
| DIT | diiodotyrosine |
| DTC | differentiated thyroid cancer |
| EBRT | external beam radiation therapy |
| eIF1A | eukaryotic translation initiation factor 1A |
| EMA | European Medical Agency |
| FAP | familial adenomatous polyposis |
| FDA | Food and Drug Administration |
| 18FDG | 18F-fluoro-2-deoxy-D-glucose |
| FNAB | fine-needle aspiration biopsy |
| FTC | follicular thyroid carcinoma |
| FVPTC | follicular variant of PTC |
| GTP | guanosine triphosphate |
| HCC | Hürtle cell carcinoma |
| HNHA | N-hydroxy-7-(2-naphthylthio) heptanamide |
| HT | hypertension |
| IDH1 | isocitrate dehydrogenase 1 |
| IDH2 | isocitrate dehydrogenase 2 |
| IMRT | intensity-modulated radiation therapy |
| KIs | kinase inhibitors |
| MAPK | mitogen-activated protein kinase |
| MEN | multiple endocrine neoplasia |
| MEN2 | multiple endocrine neoplasia type 2 |
| MIT | monoiodotyrosine |
| MKIs | multi-kinase inhibitors |
| MRI | magnetic resonance imaging |
| MTC | medullary thyroid cancer |
| ND | not defined |
| NIS | sodium iodide symporter |
| ORR | overall response rate |
| OS | overall survival |
| PAX8 | paired box 8 |
| PD | progressive disease |
| PDCT | poorly differentiated thyroid carcinoma |
| PET | positron emission tomography |
| PFS | progression-free survival |
| PI3K | phosphatidylinositol 3-kinase |
| PIK3CA | phosphatidylinositol-4,5-bisphosphate 3-kinase |
| PLC-γ | phospholipase C |
| PPARγ | peroxisome proliferator activated receptor γ |
| PPES | palmar-plantar erythrodysesthesia syndrome |
| PR | partial response |
| PTC | papillary thyroid carcinoma |
| RAI | radioactive iodine; radioiodine |
| RAIR | radioactive iodine refractory; radioiodine refractory |
| RANKL | receptor activator of nuclear factor κ-Β ligand |
| RETf | RET fusion-positive |
| RETm | RET mutation-positive |
| RTK | receptor tyrosine kinase |
| RWS | Real-Word Studies |
| SD | stable disease |
| SKIs | specific kinase inhibitors |
| T3 | triiodothyronine |
| T4 | thyroxine |
| TBSRTC | The Bethesda System for Reporting Thyroid Cytopathology |
| TC | thyroid cancer |
| TCGA | The Cancer Genome Atlas |
| TERT | telomerase reverse transcriptase |
| Tg | thyroglobulin |
| THs | thyroid hormones |
| TPO | thyroid peroxidase |
| TRK | tropomyosin receptor kinase |
| TSH | thyroid-stimulating hormone |
| USG | ultrasonography |
| WBC | white blood cell |
| WHO | World Health Organization |
| wt | wild type |